FIELD: medicine, pharmaceutics.
SUBSTANCE: group of inventions relates to medicine and deals with an immunobiological agent for treating urinary bladder cancer, based on BCG vaccine, including a peptidoglycan fragment, which contains diaminopimelic acid as a part of its structure. The group of inventions also deals with a method of applying the claimed immunobiological agent for the treatment of urinary bladder cancer.
EFFECT: group of inventions provides an increased anti-tumour activity.
5 cl, 5 ex, 5 dwg, 4 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| BCG-BASED IMMUNOBIOLOGICAL MEDICATION FOR URINARY BLADDER CANCER THERAPY AND METHOD FOR THEREOF APPLICATION | 2014 |
|
RU2571822C1 |
| PHARMACEUTICAL COMPOSITION OF PATTERN-RECOGNISING RECEPTOR LIGANDS, METHODS FOR USING IT AS IMMUNOSTIMULANT FOR TREATING INFECTION CAUSED BY BACTERIAL AND VIRAL PATHOGENS, METHOD FOR USING IT AS ADJUVANT OF VACCINES | 2012 |
|
RU2497541C1 |
| COMPOSITION COMPRISING LOW-MOLECULAR FRAGMENTS OF PEPTIDOGLICANE OF GRAM-NEGATIVE BACTERIA FOR PREVENTING OR TREATING OF HUMAN DISEASES | 2009 |
|
RU2441906C2 |
| MULTI-SPECIFIC ANTIBODIES INTENDED FOR USE IN TREATMENT OF URINARY TRACT NEOPLASM | 2017 |
|
RU2766358C2 |
| COMPOSITION OF SOLUBLE MONOMERIC AND OLIGOMERIC FRAGMENTS OF PEPTIDOGLYCAN OF THE CELL WALL OF GRAM-NEGATIVE BACTERIA, METHODS FOR PRODUCTION AND APPLICATION THEREOF | 2020 |
|
RU2765270C1 |
| METHOD OF INHIBITING PD-1/PD-L1 SIGNALING PATHWAY IN BLADDER CANCER CELLS | 2023 |
|
RU2812805C1 |
| INTERFERON BETA IMMUNOBIOLOGICAL AGENT FOR BLADDER CANCER THERAPY AND METHOD FOR USING SAME | 2014 |
|
RU2568575C1 |
| METHOD FOR PREPARING PHARMACOLOGICALLY ACCEPTABLE MIXTURE OF SUBSTANCES CONTAINING LOW-MOLECULAR INGREDIENTS OF CELL WALL PEPTIDOGLYCANE OF GRAM-NEGATIVE BACTERIA AND POSSESSING IMMUNOSTIMULATORY ACTIVITY | 2008 |
|
RU2478644C2 |
| MULTICOMPONENT VACCINE FOR IMMUNOPROPHYLAXIS AND IMMUNOTHERAPY OF DISEASES CAUSED BY OPPORTUNISTIC PATHOGENS | 2022 |
|
RU2786222C1 |
| MESOTHELINE-TARGETED CANCER VACCINES AND THEIR APPLICATION | 2018 |
|
RU2751252C1 |
